Japan has become the second major market to approve Eli Lilly’s Kisunla (donanemab) for treating early-stage Alzheimer’s disease. The drug targets amyloid plaques in the brain, which are believed to contribute to the disease’s progression, and has shown promising results in slowing cognitive decline. This approval comes as the number of dementia cases in Japan is expected to exceed 5 million by 2030.